Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

September 15, 2017: By Joan McKenna

aldeyra_logoAldeyra Therapeutics announced Sept. 12 that its lead drug candidate, ADX-102, showed positive results in a Phase IIa dose-ranging clinical trial for dry eye disease.

The Lexington, Massachusetts, company said ADX-2012 showed statistically and clinically significant improvement across multiple sign and symptom endpoints, with onset of action within one week.

ADX-102 is an aldehyde trap intended to treat ocular inflammation. ADX-102 has been tested in more than 250 patients in Phase II trials in dry eye, allergic conjunctivitis, and noninfectious anterior uveitis.

In the dry eye study, levels of malondialdehyde, a pro-inflammatory aldehyde mediator sequestered by ADX-102, were significantly reduced in the tears of patients, Aldeyra said. There were no safety concerns or serious adverse events.

The company said it plans to initiate a Phase IIb clinical trial in dry eye in the first half of 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility